REVERSAL OF BRAIN METABOLIC ABNORMALITIES FOLLOWING TREATMENT OF AIDS DEMENTIA COMPLEX WITH 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE (AZT, ZIDOVUDINE) - A PET-FDG STUDY

  • 1 May 1989
    • journal article
    • research article
    • Vol. 30  (5) , 581-590
Abstract
Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3''-azido-2'',3''-dideoxythymidine (AZT, zidovudine), and later in the course of therapy. In two patients, baseline, large focal cortical abnormalities of glucose utilization were reversed during the course of therapy. In the other two patients, the initial PET study did not reveal pronounced focal alterations, while the post-treatment scans showed markedly increased cortical glucose metabolism. The improved cortical glucose utilization was accompanied in all patients by immunologic and neurologic improvement. PET-FDG studies can detect cortical metabolic abnormalities associated with AIDS dementia complex, and may be used to monitor the metabolic improvement in response to AZT treatment.